Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New upgrade:   Journal your trades with more detail

Read How
Market News Market Pulse Stocks News ETF News Crypto News

https://immatics.com/

Contributing Author

Recent Articles by https://immatics.com/

1 hour
Immatics Announces $150 Million Underwritten Offering IMTX +9.32% GlobeNewswire
Aug-18
Immatics Announces Second Quarter 2026 Financial Results and Business Update IMTX GlobeNewswire
Jul-17
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026 IMTX GlobeNewswire
Jun-01
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting IMTX GlobeNewswire
May-31
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer IMTX GlobeNewswire
May-30
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting IMTX GlobeNewswire
May-12
Immatics Announces First Quarter 2026 Financial Results and Business Update IMTX GlobeNewswire
Apr-21
Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting IMTX GlobeNewswire
Apr-17
PRAME-directed Cell Therapy Using Immatics' TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma IMTX GlobeNewswire
Mar-05
Immatics Announces Full Year 2025 Financial Results and Business Update IMTX GlobeNewswire
Dec-11
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress IMTX GlobeNewswire
Dec-05
Immatics Announces $125 Million Underwritten Offering IMTX -14.24% GlobeNewswire
Nov-17
Immatics Announces Third Quarter 2025 Financial Results and Business Update IMTX -7.16% GlobeNewswire
Nov-12
Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps IMTX +16.10% GlobeNewswire
Oct-27
Immatics Appoints Amie Krause as Chief People Officer IMTX GlobeNewswire
Oct-20
Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium IMTX +11.04% GlobeNewswire
Oct-01
Immatics Appoints Venkat Ramanan as Chief Financial Officer IMTX +5.63% GlobeNewswire
Aug-13
Immatics Announces Second Quarter 2025 Financial Results and Business Update IMTX GlobeNewswire
May-31
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma IMTX GlobeNewswire
May-13
Immatics Announces First Quarter 2025 Financial Results and Business Update IMTX GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 1 minute for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)